Janney Montgomery Scott LLC Has $1.44 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Janney Montgomery Scott LLC lifted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 109.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,200 shares of the life sciences company's stock after purchasing an additional 9,490 shares during the quarter. Janney Montgomery Scott LLC's holdings in Illumina were worth $1,444,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Exchange Traded Concepts LLC increased its holdings in Illumina by 54.3% during the first quarter. Exchange Traded Concepts LLC now owns 220,691 shares of the life sciences company's stock worth $17,510,000 after buying an additional 77,643 shares during the last quarter. Capital Investment Services of America Inc. increased its holdings in Illumina by 13.6% during the first quarter. Capital Investment Services of America Inc. now owns 96,141 shares of the life sciences company's stock worth $7,628,000 after buying an additional 11,524 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Illumina by 65.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 33,437 shares of the life sciences company's stock worth $2,653,000 after buying an additional 13,240 shares during the last quarter. Quintet Private Bank Europe S.A. increased its holdings in Illumina by 142.3% during the first quarter. Quintet Private Bank Europe S.A. now owns 3,405 shares of the life sciences company's stock worth $270,000 after buying an additional 2,000 shares during the last quarter. Finally, Legacy Trust increased its holdings in Illumina by 5.0% during the first quarter. Legacy Trust now owns 13,298 shares of the life sciences company's stock worth $1,055,000 after buying an additional 632 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of ILMN traded up $0.63 during midday trading on Friday, hitting $94.79. The company's stock had a trading volume of 3,837,289 shares, compared to its average volume of 2,142,698. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company's fifty day simple moving average is $82.69 and its two-hundred day simple moving average is $98.98. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $15.01 billion, a price-to-earnings ratio of -15.62, a price-to-earnings-growth ratio of 1.86 and a beta of 1.32.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same quarter last year, the company posted $0.98 EPS. The company's revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Ankur Dhingra acquired 6,100 shares of the business's stock in a transaction that occurred on Monday, May 12th. The shares were bought at an average price of $81.21 per share, with a total value of $495,381.00. Following the acquisition, the chief financial officer now directly owns 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 2.60% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Royal Bank Of Canada decreased their price target on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 8th. Piper Sandler lowered their target price on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. Stephens reissued an "overweight" rating and set a $105.00 price target on shares of Illumina in a report on Tuesday, May 20th. Barclays reissued an "underweight" rating and set a $85.00 price target (up from $77.00) on shares of Illumina in a report on Tuesday, June 24th. Finally, Guggenheim dropped their price target on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Illumina presently has an average rating of "Moderate Buy" and a consensus price target of $127.39.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.